Millennium Management LLC bought a new position in shares of Crispr Therapeutics AG (NASDAQ:CRSP) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 106,538 shares of the company’s stock, valued at approximately $4,366,000. Millennium Management LLC owned 0.19% of Crispr Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also modified their holdings of CRSP. BNP Paribas Arbitrage SA acquired a new stake in shares of Crispr Therapeutics during the second quarter worth $41,000. Aperio Group LLC acquired a new stake in shares of Crispr Therapeutics in the 2nd quarter worth about $153,000. Swiss National Bank increased its holdings in shares of Crispr Therapeutics by 28.6% in the 2nd quarter. Swiss National Bank now owns 48,600 shares of the company’s stock worth $2,289,000 after acquiring an additional 10,800 shares during the period. National Asset Management Inc. acquired a new stake in shares of Crispr Therapeutics in the 2nd quarter worth about $362,000. Finally, Wells Fargo & Company MN increased its holdings in shares of Crispr Therapeutics by 23.9% in the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after acquiring an additional 116,540 shares during the period. 49.82% of the stock is currently owned by institutional investors.
CRSP traded up $0.12 during midday trading on Friday, hitting $59.44. 1,391,345 shares of the company’s stock traded hands, compared to its average volume of 941,091. The stock’s fifty day simple moving average is $65.98 and its 200-day simple moving average is $51.14. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. Crispr Therapeutics AG has a one year low of $28.95 and a one year high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating the consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The firm had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. As a group, research analysts expect that Crispr Therapeutics AG will post 0.65 EPS for the current fiscal year.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $62.00, for a total transaction of $465,000.00. Following the sale, the director now owns 7,500 shares in the company, valued at $465,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now directly owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. In the last three months, insiders sold 56,118 shares of company stock worth $3,620,760. Insiders own 21.40% of the company’s stock.
A number of analysts recently weighed in on the stock. TheStreet raised shares of Crispr Therapeutics from a “d” rating to a “c” rating in a report on Monday, October 28th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Crispr Therapeutics in a report on Friday, December 6th. BidaskClub lowered shares of Crispr Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. William Blair upgraded shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, November 19th. Finally, Chardan Capital restated a “buy” rating and set a $72.50 price objective on shares of Crispr Therapeutics in a research report on Monday, November 18th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $71.38.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: What is the market perform rating?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.